Abstract
Transgenic mice (K5-PKCα) in which the keratin 5 promoter directs the expression of protein kinase C-α (PKCα) to epidermal keratinocytes display a 10-fold increase in PKCα protein in their epidermis and alterations in phorbol ester-induced cutaneous inflammation [J Cell Science 1999;112:3497–3506]. In the current study, we have used these K5-PKCα mice to examine the role of PKCα in keratinocyte phospholipid metabolism/eicosanoid production and cutaneous inflammation. Primary keratinocytes from wild-type and transgenic mice were prelabeled in culture with [3H]arachidonic acid (AA) and subsequently treated with TPA. Compared with wild-type keratinocytes, K5-PKCα keratinocytes displayed a 2-fold increase in AA release. TPA treatment resulted in the phosphorylation of cPLA2. PKC inhibitors GF-109203X or H7, but not mitogen-activated protein/extracellular signal-regulated protein kinase (MEK) inhibitor PD 98059, could inhibit phosphorylation and AA release. Topical 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of K5-PKCα mice resulted in a 5-fold increase in epidermal COX-2 induction and a 2- to 3-fold increase in prostaglandin (PG) E2 levels above that observed in TPA-treated wild-type mice. PD 98059, GF-109203X, or H7 could block cyclooxygenase-2 (COX-2) induction by TPA. Because C/EBPβ, a basic leucine zipper transcription factor, can be activated via a PKCα/mitogen-activated protein kinase pathway and can influence COX-2 expression, we examined whether C/EBPβ is involved in TPA-induced epidermal COX-2 expression. TPA-induced COX-2 expression was similar in C/EBPβ nullizygous and wild-type mice. In summary, our results indicate that epidermal PKCα coordinately regulates cPLA2 activity and COX-2 expression resulting in increased levels of AA and PGE2. Furthermore, PKCα-induced AA release and cPLA2phosphorylation are independent of MEK, whereas PKCα-induced COX-2 expression and PGE2 production are MEK-dependent and C/EBPβ-independent events.
Footnotes
- Received May 15, 2000.
- Accepted December 27, 2000.
-
Send reprint requests to: Robert C. Smart, Ph.D., Cell Signaling and Cancer Group, Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, NC 27695-7633. E-mail: rcsmart{at}unity.ncsu.edu
-
This work was supported by Grant CA46637 from the National Cancer Institute (R.C.S.).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|